Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BIO-TECHNE (TECH) EBIT Margin: 2009-2025

Historic EBIT Margin for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to 16.63%.

  • BIO-TECHNE's EBIT Margin rose 282.00% to 16.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.03%, marking a year-over-year decrease of 725.00%. This contributed to the annual value of 8.38% for FY2025, which is 945.00% down from last year.
  • BIO-TECHNE's EBIT Margin amounted to 16.63% in Q3 2025, which was up 320.94% from -7.53% recorded in Q2 2025.
  • Over the past 5 years, BIO-TECHNE's EBIT Margin peaked at 2,815.85% during Q3 2022, and registered a low of -7.53% during Q2 2025.
  • Its 3-year average for EBIT Margin is 16.45%, with a median of 15.96% in 2024.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 279,132bps in 2022, then crashed by 279,568bps in 2023.
  • Over the past 5 years, BIO-TECHNE's EBIT Margin (Quarterly) stood at 23.15% in 2021, then spiked by 184bps to 25.00% in 2022, then slumped by 1,106bps to 13.94% in 2023, then skyrocketed by 202bps to 15.96% in 2024, then spiked by 282bps to 16.63% in 2025.
  • Its EBIT Margin was 16.63% in Q3 2025, compared to -7.53% in Q2 2025 and 12.24% in Q1 2025.